So far, abemaciclib is the only one of the CDK4/6i approved for HR+/HER2− advanced or metastatic BC as a monotherapy, based on results from the MONARCH-1 (NCT02102490) phase II clinical trial. Here, ERBB2 is linked to breast cancer.